Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/19316
Title: Pazopanib-Induced Reversible Left Ventricular Systolic Dysfunction
Authors: Roongsangmanoon W.
Wattanawinitchai K.
Charonpongsuntorn C.
Chonmaitree P.
Wongsoasup A.
Rattanajaruskul N.
Angkananard T.
Keywords: bisoprolol
furosemide
hydralazine
isosorbide dinitrate
losartan
pazopanib
protein tyrosine kinase inhibitor
sunitinib
troponin
valsartan
aged
Article
breathing disorder
breathing rate
cardiotoxicity
cardiovascular magnetic resonance
case report
clinical article
computer assisted tomography
diastolic dysfunction
drug withdrawal
dyspnea
fatigue
heart failure
heart left ventricle ejection fraction
heart left ventricle function
heart ventricle arrhythmia
human
hypertension
left ventricular systolic dysfunction
lung metastasis
male
nuclear magnetic resonance imaging
ophthalmoscopy
orthopnea
oxygen saturation
renal cell carcinoma
soft tissue sarcoma
systolic dysfunction
tachycardia
transthoracic echocardiography
Issue Date: 2022
Abstract: Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. The authors describe a patient with advanced renal cell carcinoma who developed severe hypertension and severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon treatment interruption. © JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123318091&doi=10.35755%2fjmedassocthai.2022.S01.00030&partnerID=40&md5=0dc61225497cf3b9c8c93a9208cc471c
http://ir.swu.ac.th/jspui/handle/123456789/19316
ISSN: 1252208
Appears in Collections:Scopus 2022 (2 Feb)

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.